Skip to main content
SpringerLink
Log in
Book cover

Dermatomyositis pp 169–178Cite as

Drug-Induced Dermatomyositis

  • Chapter

Certain drugs seem to be capable of inducing both the cutaneous and muscle manifestations of DM. Beickert and Kühne are attributed as being the first to recognize that a drug might induce DM [1]. In 1960, they reported the case of a patient who developed DM after chlorpromazine treatment. Various medications have been reported that may cause muscle damage and skin lesions — drug-induced dermatomyositis (DI-DM) or syndromes that resemble DM (DM-like syndrome) [2]. During the last 45 years, more than 40 therapeutic substances have been reported that induce DM or PM as adverse reaction of their activity (Table 24.1). In recent years, both the number of observed cases of drug-induced DM and the list of the culprit medicines that provoke these clinical features have increased [3]. The association of drugs and DM/PM may present as follow:

  1. (i)

    Induction of clinical features typical for classic DM

  2. (ii)

    Occurrence of cutaneous DM-like lesions without muscle damage — i.e., amyopathic DM

  3. (iii)

    Provocation of PM

  4. (iv)

    Development of myalgia or muscle damage

  5. (v)

    Induction of serum enzyme changes only [2]

Non-steroidal anti-inflammatory drugs (NSAIDs), lipid-lowering agents, anti-infectious, antineoplastic medicines, vaccines, radiotherapy, and other nonrelated drugs are of particular interest in induction of DM.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   149.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beickert A, Kühne W. Dermatomyositis mit Immunleucopenie, Phenothiazinschädigung. Schweiz Med Wochenschr 1960; 90: 132–135.

    PubMed  CAS  Google Scholar 

  2. Dourmishev A, Dourmishev L. Dermatomyositis and drugs. Adv Exp Med Biol 1999; 455: 187–191.

    PubMed  CAS  Google Scholar 

  3. Dourmishev LA, Stomonjakova SR, Dourmishev AL. D-penicillamine induced polymyositis and morphea dissemination in woman with Hashimoto thyreoiditis. J Eur Acad Dermatol Venereol 2002; 16: 538–539.

    Article  PubMed  CAS  Google Scholar 

  4. Kolosi R, Bahloul Z, Hachicha J, et al. Dermatomyositie induite par la d-pénicillamine au cours d'une polyarthrite rheumatoide. A propos d'un cas avec revue de la littérature. Rev. Rheum Mal Osteo Articulaires 1992; 59: 341–344.

    Google Scholar 

  5. Chapurlat R, Tebib JG, Noel E, et al. Dermatomyositis induite par la d-pénicillamine au cours d'une polyarthrite rheumatoide. Rheumatologie 1995; 47: 203–207.

    Google Scholar 

  6. Doyle DR, McCurely TL, Sergent JS. Fatal polymyositis in d-penicillamine-treated rheumatoid arthritis. Ann Intern Med 1983; 98: 327–330.

    PubMed  CAS  Google Scholar 

  7. Wright GD, Wilson C, Bell AL. D-penicillamine induced polymyositis causing complete heart block. Clin Rheumatol 1994; 13: 80–82.

    Article  PubMed  CAS  Google Scholar 

  8. Grob JJ, Collet AM, Bonerandi JJ: Dermatomyositis-like syndrome induced by nonsteroid anti-inflammatory agents. Dermatologica 1989; 178: 178.

    Article  Google Scholar 

  9. Ross NS, Hoppel CL. Partial muscle carnitine palmitoyltransferase-A deficiency. Rhabdomy-olysis associated with transiently decreased muscle carnitine content after ibuprofen therapy. JAMA 1987; 257(1): 62–65.

    Article  PubMed  CAS  Google Scholar 

  10. Curran JJ, Jamieson T W. Dermatomyositis-like syndrome associated with phenylbutazone therapy. J Rheumatol 1987; 14(2): 397–398.

    PubMed  CAS  Google Scholar 

  11. Shelly WB. Birch pollen and aspirin psoriasis. A study in salicylate hypersensitivity. JAMA 1964; 189: 985–958.

    Google Scholar 

  12. Vela-Casasempere P, Borras-Blasco J, Navarro-Ruiz A. Alfuzosin-Xatral®-associated dermato-myositis. Br J Rheumatol 1998; 37: 1135–1136.

    Article  PubMed  CAS  Google Scholar 

  13. Schalke BB, Schmidt B, Toyka K, et al. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992; 111: 649–650.

    Google Scholar 

  14. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis. Br J Rheuma-tol 1994; 32(2): 199.

    Google Scholar 

  15. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust NZ J Med 1995; 25: 745–746.

    CAS  Google Scholar 

  16. Ridriguez-Gacia JI, Serrano Commino M. Lovastatin-associated dermatomyositis. Postgrad Med J 1996; 72: 694.

    Article  Google Scholar 

  17. Noël B, Cerottini J P, Pires A, et al. Atorvastatine et dermatomyositis. Ann Dermatol Venereol 2000; 127: 4S77–227.

    Google Scholar 

  18. Pierce IR, Wysowski D, Gross T P. Myopathy and rhabdomyolysis, associated with lovastatin– gemfibrocil combination therapy. JAMA 1990; 264: 71–75.

    Article  PubMed  CAS  Google Scholar 

  19. Deslypere J P, Vermeulen A. Rhabdomyolysis with simvastatin. Ann Intern Med 1991; 114: 342.

    PubMed  CAS  Google Scholar 

  20. Wallace CS, Mueller BA. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs. Ann Pharmacol 1992; 26: 190–192.

    CAS  Google Scholar 

  21. Zuech P, Pauwels C, Duthoit C, et al. Pravastatin-induced dermatomyositis. Rev Med Interne 2005; 26: 897–902 [French].

    PubMed  CAS  Google Scholar 

  22. Thual N, Penven K, Chevallier JM, et al. Fluvastatin-induced dermatomyositis. Ann Dermatol Venereol 2005; 132(12): 996–999 [French].

    Article  PubMed  CAS  Google Scholar 

  23. Dourmishev LA, Dourmishev AL. Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations. Exp Opin Drug Saf 2008; 4: 421–433.

    Article  Google Scholar 

  24. McDonagh J, Winocour P, Walker DJ. Musculoskeletal manifestations during simvastatin therapy. Br J Rheumatol 1992; 32: 647–648.

    Article  Google Scholar 

  25. al-Jubouri M, Briston PG, Sinclair D, et al. Myxoedema revealed by simvastatin-induced myopathy. Br Med J 1994; 308: 588.

    CAS  Google Scholar 

  26. Guijaro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490–500.

    Google Scholar 

  27. Erel A, Toros P, Tokcaer AB, et al. Amyopathic dermatomyositis. Int J Dermatol 2000; 39: 771–773.

    Article  PubMed  CAS  Google Scholar 

  28. Price CJ, Frankel J P, Hammans SR. Palatal palsy in dermatomyositis. Eur J Neurol 2001; 8(2): 197–198.

    Article  PubMed  CAS  Google Scholar 

  29. Mastaglia FL. Adverse effects of drugs on muscle. Drugs 1982; 24: 304–321.

    Article  PubMed  CAS  Google Scholar 

  30. Sauvaget F, Piette JC, Herson S, et al. Fenofibrate-induced polymyositis. Rev Med Interne 1991; 12(1): 52–54 [French].

    PubMed  CAS  Google Scholar 

  31. Fusella J, Strosberg JM. Polymyositis exacerbated by gemfibrocil. J Rheumatol 1990; 17: 572.

    PubMed  CAS  Google Scholar 

  32. Richard M, Trucheter F, Friedel J, et al. Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol 1989; 21: 797–799.

    Article  PubMed  CAS  Google Scholar 

  33. Ruiz-Genao D P, Sanz-Sánchez T, Bartolomé-González B, et al. Dermatomyositis-like reaction induced by chemotherapeutical agents. Int J Dermatol 2002; 41: 885–887.

    Article  PubMed  CAS  Google Scholar 

  34. Harris AL, Smith IE, Snaith M. Tamoxifen-induced tumor regression associated with der-matomyositis. Br Med J 1982; 284: 1674.

    Article  CAS  Google Scholar 

  35. Akiyama C. Osada A, Sou K, et al. A case of dermatomyositis triggered by tegafur. Acta Derm Venereol (Stockh) 1997; 77: 490.

    CAS  Google Scholar 

  36. Monk BL, Pembroke AC. Dermatomyositis after radiotherapy. Br J Dermatol 1983; (Suppl 24): 103.

    Google Scholar 

  37. Senet P, Aractingi S, Porneuf M, et al. Hydroxyurea-induced dermatomyositis-like eruption. Br J Dermatol 1995; 133: 455–459.

    Article  PubMed  CAS  Google Scholar 

  38. Bahadoran P, Castanet J, Lacour J P, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol 1996; 134: 1161–1163.

    Article  PubMed  CAS  Google Scholar 

  39. Suehiro M, Kishimoto S, Wakabayashi T, et al. Hydroxyurea dermatopathy with a dermato-myositis-like eruption and a large leg ulcer. Br J Dermatol 1998; 139: 748–749.

    Article  PubMed  CAS  Google Scholar 

  40. Velez A, Lopez-Rubio F, Moreno JC. Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis. Clin Exp Dermatol 1998; 23: 94–95.

    Article  PubMed  CAS  Google Scholar 

  41. Rocamora V, Puig L, Alomar A. Dermatomyositis-like eruption following hydroxyurea therapy. J Eur Acad Dermatol Venereol 2000; 14: 227–228.

    Article  PubMed  CAS  Google Scholar 

  42. Oh ST, Lee DW, Lee JY, et al. Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption. J Am Acad Dermatol 2003; 49(2): 339–341.

    Article  PubMed  Google Scholar 

  43. Marie I, Joly P, Levesque H, et al. Pseudo-dermatomyositis as a complication of hydroxyurea therapy. Clin Exp Rheumatol 2000; 18: 536–537.

    PubMed  CAS  Google Scholar 

  44. Varma S, Lanigan S W. Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis. Clin Exp Dermatol 1999; 24: 164–166.

    Article  PubMed  CAS  Google Scholar 

  45. Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermatopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1997; 36: 178–182.

    Article  PubMed  CAS  Google Scholar 

  46. Kirby B, Rogers S. Hydroxyurea-induced dermatopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1998; 38: 178–182.

    Google Scholar 

  47. Bouldouyre MA, Avril MF, Gaulier A, et al. Association of cutaneous side-effects of hydrox-yurea and neuroendocrine carcinoma. Eur J Dermatol 2005; 15: 268–270.

    PubMed  Google Scholar 

  48. Katou Y, Kanoh Y, Bando M, et al. S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex. Nature 2003; 424(6952): 1078–1083.

    Article  PubMed  CAS  Google Scholar 

  49. Krishnan K, Adams P, Silveira S, et al. Therapy-related acute myeloid leukaemia following immu-nosuppression with azathioprine for polymyositis. Clin Lab Haematol 1994; 16: 285–289.

    Article  PubMed  CAS  Google Scholar 

  50. Arnold JA, Ranson SA, Abdalla SH. Azathioprine-associated acute myeloid leukaemia with trilineage dysplasia and complex karyotype: a case report and review of the literature. Clin Lab Haem 1999; 21: 289–292.

    Article  CAS  Google Scholar 

  51. Kamel OW, van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein– Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyosi-tis. N Engl J Med 1993; 328: 1317–1321.

    Article  PubMed  CAS  Google Scholar 

  52. Bittar B, Rose CD. Early development of Hodgkin's lymphoma in association with the use of methotrexate for the treatment of dermatomyositis. Ann Rheum Dis 1995; 54: 607–608.

    Article  PubMed  CAS  Google Scholar 

  53. Chai C, White WL, Shea CR, et al. Epstein–Barr virus-associated lymphoproliferative disorders primarily involving the skin. J Cutan Pathol 1999; 26: 242–247.

    Article  PubMed  CAS  Google Scholar 

  54. Callen J P. Dermatomyositis and multiple malignancies in a patient treated with methotrexate. J Surg Oncol 1983; 24: 113–116.

    Article  PubMed  CAS  Google Scholar 

  55. Roddy E, Couriney PA, Morrisw A. Non-Hodgkin's lymphoma in a patient with refractory der-matomyositis which had been treated with infliximab. Rheumatology 2002; 41: 1194–1195.

    Article  PubMed  CAS  Google Scholar 

  56. Parker C W. Drug allergy (in three parts). N Engl J Med 1975: 292(10): 511–514, 732–736, 957–960.

    PubMed  CAS  Google Scholar 

  57. Mackie BS, Mackie LE. Systemic lupus erythematosus-dermatomyositis induced by sulpha-cetamide eye drops. Australas J Dermatol 1979; 20(1): 49–50.

    Article  PubMed  CAS  Google Scholar 

  58. Fayolle J, Vallon C, Claudy E, et al. Dermatomyositis induite par l'isoniazide. Lyon Med 1975; 223: 135.

    Google Scholar 

  59. Bessen LJ, Green GB, Louie E, et al. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC. New Engl J Med 1988; 318: 708.

    PubMed  CAS  Google Scholar 

  60. Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 332: 1098–1105.

    Google Scholar 

  61. Camus J P, Koeger AC, Nahoul K, et al. Isolated muscular tuberculosis treated with corticos-teroids. Developing outbreak of dermatomyositis under rifampicin treatment. 2 cases. Ann Med Interne (Paris) 1987; 138: 524–526 [French].

    CAS  Google Scholar 

  62. Cotterill JA, Shapiro H. Dermatomyositis after immunization. Lancet 1978; 2(8100): 1158–1159.

    Article  PubMed  CAS  Google Scholar 

  63. Kass F, Straume S, Mellbaye OJ, et al. Dermatomyositis associated with BCG vaccination. Scand J Rheumatol 1979; 8: 187–191.

    Article  PubMed  CAS  Google Scholar 

  64. Mackie B. Dermatomyositis induced by drugs. Aust J Dermatol 1966; 8: 249.

    PubMed  CAS  Google Scholar 

  65. Zangemeister WH, Weisner B. A progressive systemic sclerosis-like disease due to anticon-vulsive therapy? Fortschr Neurol Psychiatr Grenzgeb 1977; 45(9): 501–507 [German].

    PubMed  CAS  Google Scholar 

  66. Dimachkie MM, Vriesendorp FJ, Heck KA. Phenytoin-induced dermatomyositis: case report and literature review. J Child Neurol 1998; 13: 577–580.

    Article  PubMed  CAS  Google Scholar 

  67. Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000; 17: 64–69.

    Article  PubMed  CAS  Google Scholar 

  68. Gomez Rodriguez N, Zulaica Garate A. Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide. An Med Interna 2005; 22: 300–301 [Spanish].

    PubMed  CAS  Google Scholar 

  69. Lee AN, Werth V P. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol 2004; 140: 723–727.

    Article  PubMed  Google Scholar 

  70. Burger RA, Torres AR, Warren R P, et al. Echinacea-induced cytokine production by human macrophages. Int J Immunopharmacol 1997; 19: 371–379.

    Article  PubMed  CAS  Google Scholar 

  71. Hirahashi T, Matsumoto M, Hazeki K, et al. Activation of the human innate immune system by Spirulina: augmentation of interferon production and NK cytotoxicity by oral administration of hot water extract of Spirulina platensis. Int Immunopharmacol 2002; 2: 423–434.

    Article  PubMed  CAS  Google Scholar 

  72. Pugh N, Pasco DS. Characterization of human monocyte activation by a water soluble preparation of Aphanizomenon flos-aquae. Phytomedicine 2001; 8: 445–453.

    Article  PubMed  CAS  Google Scholar 

  73. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol 1998; 39(6): 899–920.

    Article  PubMed  CAS  Google Scholar 

  74. Hess E. Drug-related lupus. N Engl J Med 1988; 318: 1460–1462.

    PubMed  CAS  Google Scholar 

  75. Price EJ, Venables PT. Drug-induced lupus. Drug Safety 1995; 12: 283–290.

    Article  PubMed  CAS  Google Scholar 

  76. Kubo M, Ihn H, Yazawa Y, et al. Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis. J Invest Dermatol 1999; 112: 711–715.

    Article  PubMed  CAS  Google Scholar 

  77. Wilson CL, Bradlow A, Wonjarowska F. Cutaneous problems with drug therapy in rheumatoid arthritis. Int J Dermatol 1991; 30: 148–149.

    Article  PubMed  CAS  Google Scholar 

  78. Kamenska V, Dourmishev L, Dourmishev A, et al. Quantitative structure–activity relationship modeling of dermatomyositis activity of drug chemicals. Arzneimittelforschung 2006; 56(12): 856–865.

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

(2009). Drug-Induced Dermatomyositis. In: Dermatomyositis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79313-7_24

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79313-7_24

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79312-0

  • Online ISBN: 978-3-540-79313-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation